Generation of monoclonal antibodies against 17α-hydroxyprogesterone for newborn screening of congenital adrenal hyperplasia

García, Greilys Morejón; Rosa, Iria García de la; Reyes, Ernesto Carlos González; Torres, Armin Ramos; Guerra, Joel; Marín, Milenen Hernández; Mora, Pedro L. Pérez; Carballo, Sadys Feal; Delfino, Yesdiley Lafita; Infante, Maylín Pupo; Castells, Elisa; Poloshkov, Alik Rosabal; Pérez, Liliana

doi:10.1016/j.cca.2018.07.019

Cited by 5 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A report in 2019 described the 20-year SUMA ® external QA program, a program limited exclusively to laboratories using the SUMA ® technology and confirmed its relevance in supporting quality NBS [ 1202 ]. Recently research reports have included CF test development [ 1203 , 1204 , 1205 ] and test improvement for CAH [ 1206 ] and CH [ 1207 , 1208 ]. As part of general health screening for newborns, attention has recently been given to piloting a new POC NHS procedure.…”

Section: Resultsmentioning

confidence: 99%

Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020–2023)

Therrell,

Padilla,

Borrajo

et al. 2024

IJNS

View full text Add to dashboard Cite

Newborn bloodspot screening (NBS) began in the early 1960s based on the work of Dr. Robert “Bob” Guthrie in Buffalo, NY, USA. His development of a screening test for phenylketonuria on blood absorbed onto a special filter paper and transported to a remote testing laboratory began it all. Expansion of NBS to large numbers of asymptomatic congenital conditions flourishes in many settings while it has not yet been realized in others. The need for NBS as an efficient and effective public health prevention strategy that contributes to lowered morbidity and mortality wherever it is sustained is well known in the medical field but not necessarily by political policy makers. Acknowledging the value of national NBS reports published in 2007, the authors collaborated to create a worldwide NBS update in 2015. In a continuing attempt to review the progress of NBS globally, and to move towards a more harmonized and equitable screening system, we have updated our 2015 report with information available at the beginning of 2024. Reports on sub-Saharan Africa and the Caribbean, missing in 2015, have been included. Tables popular in the previous report have been updated with an eye towards harmonized comparisons. To emphasize areas needing attention globally, we have used regional tables containing similar listings of conditions screened, numbers of screening laboratories, and time at which specimen collection is recommended. Discussions are limited to bloodspot screening.

show abstract

Section: Resultsmentioning

confidence: 99%

Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020–2023)

Therrell,

Padilla,

Borrajo

et al. 2024

IJNS

View full text Add to dashboard Cite

show abstract

“…With a designed family of over 10,000 NTF2s with diverse pocket geometries in hand, we used RIFdock 7 to place six chemically and structurally distinct small-molecules in the central pocket of these backbones ( Fig. 1B ), including the stress hormone cortisol (HCY) 18 , the anticoagulant warfarin (WRF) 19 , the muscle relaxant rocuronium (ROC) 20 , the anticoagulant apixaban (APX) 21 , the active metabolite of the anticancer drug irinotecan (SN-38) 22 , and the hormone 17-α-hydroxyprogesterone (OHP) 23 ( Fig. 2A ).…”

Section: Computational Design Of Small-molecule-binding Proteinsmentioning

confidence: 99%

Small-molecule binding and sensing with a designed protein family

Lee,

Pellock,

Norn

et al. 2023

Preprint

View full text Add to dashboard Cite

Despite transformative advances in protein design with deep learning, the design of small-molecule–binding proteins and sensors for arbitrary ligands remains a grand challenge. Here we combine deep learning and physics-based methods to generate a family of proteins with diverse and designable pocket geometries, which we employ to computationally design binders for six chemically and structurally distinct small-molecule targets. Biophysical characterization of the designed binders revealed nanomolar to low micromolar binding affinities and atomic-level design accuracy. The bound ligands are exposed at one edge of the binding pocket, enabling thede novodesign of chemically induced dimerization (CID) systems; we take advantage of this to create a biosensor with nanomolar sensitivity for cortisol. Our approach provides a general method to design proteins that bind and sense small molecules for a wide range of analytical, environmental, and biomedical applications.

show abstract

“…68-96-2), with the name hydroxyprogesterone, is an endogenous progesterone-like steroid hormone similar to progesterone. It is an important method for diagnosing and screening congenital adrenal hyperplasia in newborns . OHP has been used preventively from the 12th to 37th week of pregnancy, especially in high-risk groups of premature delivery (such as women with a history of premature delivery or spontaneous abortion).…”

Section: Introductionmentioning

confidence: 99%

“…It is an important method for diagnosing and screening congenital adrenal hyperplasia in newborns. 2 OHP has been used preventively from the 12th to 37th week of pregnancy, especially in high-risk groups of premature delivery (such as women with a history of premature delivery or spontaneous abortion). In addition, 17-α hydroxyprogesterone (OHP) can also effectively treat neutrophil airway inflammation, including reducing blood and respiratory neutrophils, 3 and controlling the nonincrease in eosinophil 4 count.…”

Section: Introductionmentioning

confidence: 99%

Solubility, Thermodynamic Parameters, and Dissolution Properties of 17-α Hydroxyprogesterone in 13 Pure Solvents

Zhao,

Pan,

Xiong

et al. 2024

ACS Omega

View full text Add to dashboard Cite

The static gravimetric method was used to measure the solubility of 17-α hydroxyprogesterone (OHP) in 13 pure solvents ranging from 278.15 to 323.15 K. The results indicate that the experimental solubility of OHP increases with increasing temperature. The experimental solubility data were correlated by the selected van’t Hoff model, λh model, modified Apelblat model, Yaws model, and nonrandom two-liquid (NRTL) model. The fitting results show that the Yaws model can give better correlation results by fitting 13 different pure solvent systems. Based on the NRTL equation, the thermodynamic analysis of solubility data showed that the mixing process was spontaneous. The Hansen solubility parameters (HSPs) and solvent effect were applied to explore these solubility characteristics. Finally, the thermodynamic properties Δsol H°, Δsol S°, Δsol G°, %ξH, and %ξTS were calculated by the van’t Hoff model equation. The results showed that Δsol H°, Δsol S°, and Δsol G° are all positive values, indicating that the dissolution of OHP in the selected solvent is an endothermic reaction with increasing entropy.

show abstract

Generation of monoclonal antibodies against 17α-hydroxyprogesterone for newborn screening of congenital adrenal hyperplasia

Cited by 5 publications

References 14 publications

Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020–2023)

Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020–2023)

Small-molecule binding and sensing with a designed protein family

Solubility, Thermodynamic Parameters, and Dissolution Properties of 17-α Hydroxyprogesterone in 13 Pure Solvents

Contact Info

Product

Resources

About